Document:

License Agreement

 EXHIBIT 10.21 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “***”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
 LICENSE AGREEMENT 
 This License Agreement, effective as of August 1, 2006 (the “Effective Date”), is by and
between Phenomix Corporation, a corporation organized under the laws of Delaware (“Phenomix”) and ActivX Biosciences, Inc., a corporation organized under the laws of Delaware (“ActivX”). Phenomix and ActivX may be referred to
individually herein as a “Party” or collectively as the “Parties.” 
 WITNESSETH 
 WHEREAS, the Parties have been engaged in a dispute regarding their respective rights to practice certain items of intellectual property (the
“Dispute”); and 
 WHEREAS, the Parties have agreed to settle the Dispute; and 
 WHEREAS, in connection with the settlement of the Dispute ActivX desires to receive a license for the use of certain items of intellectual
property, and Phenomix is willing to grant such a license to ActivX. 
 NOW THEREFORE, in consideration of the mutual promises and
agreements set forth herein, the settlement of the Dispute, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Phenomix and ActivX intending to be legally bound, hereby agree as follows:

  

	1.	Definitions. 

 Capitalized terms used in this
Agreement and not otherwise defined herein shall have the meanings set forth below: 
 “Affiliate” means any person, natural
or otherwise, that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with a Party. For purposes of this definition, “control” means (a) the direct or indirect ownership
of more than fifty percent (50%) (or such maximum lesser percentage allowed to be owned by a foreign owner in a particular jurisdiction), of the outstanding voting securities of such entity, or (b) the ability to affect management
control or possessing decision making authority of such entity through whatever means. 
 “Agreement” means this License
Agreement, together with all exhibits annexed hereto, as the same shall be modified and in effect from time to time. 

 “Co-Exclusive” means with respect to a designated set of rights, a limitation upon the
number of parties legally entitled to practice such rights. For purposes of this Agreement, Co-Exclusive rights shall be shared, subject to the terms and conditions of this Agreement, only by ActivX, Phenomix, and their respective Affiliates and
permitted sublicensees. 
 “Confidential Information” means all information and data provided by the Parties to each other
hereunder in written or other tangible form and marked as confidential or, if disclosed orally or displayed, identified as confidential at or about the time of disclosure and confirmed in summary written form as confidential within thirty
(30) days after disclosure, except any portion thereof which: 
 (a) is known to the receiving Party, as evidenced by the
receiving Party’s written records, before receipt thereof under this Agreement or any other agreement between the Parties hereto providing for confidentiality; 
 (b) is disclosed to the receiving Party by a third person who is not under an obligation of confidentiality to the disclosing Party
hereunder with respect to such information and who otherwise has a right to make such disclosure; 
 (c) is or becomes
generally known in the trade through no fault of the receiving Party; 
 (d) is independently developed by the receiving
Party, without resort to the disclosing Party’s confidential information, by persons having no access thereto, as evidenced by the receiving Party’s written records; or 
 (e) is required to be disclosed by applicable statute, rule or regulation of any court or regulatory authority with competent
jurisdiction; provided that the Party whose information is to be disclosed shall be notified as soon as possible and the Party that is being required to disclose such information shall, if requested by the party whose information is to be disclosed,
use reasonable good faith efforts, at the expense of the requesting Party, to assist in seeking a protective order (or equivalent) with respect to such disclosure or otherwise take reasonable steps to avoid making such disclosure. 
 “Control” or “Controlled” shall mean the legal authority or right of a Party to grant a license or sublicense of
intellectual property rights to the other Party, without breaching the terms of any agreement with a third party, infringing upon the intellectual property rights of a third party, or misappropriating the proprietary or trade secret information of a
third party. 
 “Covered Products” means in a given country any item(s) covered by a Valid Claim that, but for the license
granted to ActivX under the Phenomix Licensed Patent Rights, such Valid Claim would be infringed by the manufacture, use or sale of such item(s) in such country. 

 “Improvements” means all improvements, variations, updates, modifications, and
enhancements made to or under the Phenomix Licensed Patent Rights during the term of the Agreement and Controlled by a Party, which are patentable, whether or not the subject of any patent application, which further are entirely supported by the
original specification and are entitled to the priority date of a patent application or a patent under Phenomix Licensed Patent Rights, and specifically excluding New Technology. 
 “Phenomix Licensed Patent Rights” means with respect to compounds within the Markush structures set forth on Exhibit A, the claims of
(i) any patent or patent application listed on Exhibit A (but specifically excluding claims to the extent related to compounds within the Markush structures set forth on Exhibit B and all other compound structures not set forth on Exhibit A),
(ii) any patents or patent applications which are entitled to claim priority from the patents or patent applications listed on Exhibit A, or (iii) any patents and patent applications which claim priority from one or more of the U.S.
provisional applications from which * * *claims priority, which are entitled to claim the priority of the patent applications listed on Exhibit A, but in each of the foregoing instances, specifically excluding any New Technology or Improvements. For
the avoidance of doubt, if a compound is encompassed by both Exhibit B and Exhibit A, then the compound shall be deemed an Exhibit B compound only, and is not within the Phenomix Licensed Patent Rights. 
 “New Technology” means any inventions or claims thereof Controlled by a Party, which constitute advancements, developments, or
improvements made after the Effective Date, whether or not patentable and whether or not the subject of any patent application, which are not entirely supported by the original specification, and are not entitled to the priority date, of a patent
application or patent contained within Phenomix Licensed Patent Rights. 
 “Term” means that this Agreement shall, subject
to the early termination provisions specifically provided for herein, have a term from the Effective Date until expiration of the last to expire Valid Claim licensed to ActivX pursuant to this Agreement. 
 “Territory” means worldwide. 
 “Valid Claim” means a claim present in any of the Phenomix Licensed Patent Rights which shall not have been withdrawn, canceled or disclaimed, nor held or admitted to be invalid, unenforceable or unpatentable by a court or
other appropriate body of competent jurisdiction in an unappealed or unappealable decision and which has not been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise. 
  

	2.	Licenses. 

 2.1 Grant. Subject to
terms and conditions of this Agreement including, but not limited to, the reservation of rights set forth below, Phenomix hereby grants to ActivX, a Co-Exclusive right and license under Phenomix Licensed Patent Rights to make, have made, use, offer
to sell, sell and import the Covered Products in the Territory. 

	* * *	Confidential Information, indicated by ***, has been omitted from this filing and filed separately with the Securities and Exchange Commission. 

 2.2 Sublicensing. ActivX shall not be entitled to sublicense the Phenomix Licensed Patent Rights
except (a) in connection with the bona fide assignment or grant of license rights under ActivX’s intellectual property rights, other than the Phenomix Licensed Patent Rights, to a collaborator or strategic partner receiving the right to
develop or commercialize one or more ActivX drug candidates or drug products, the making, using, or selling of which would infringe the Phenomix Licensed Patent Rights, or (b) as otherwise consented to by Phenomix in writing. To be effective,
sublicenses granted by a Party pursuant to clause (a) above shall be preceded by thirty (30) days’ advance written notice to the other Party. 
 2.3 Reservation of Rights. Phenomix reserves all rights in the Phenomix Licensed Patent Rights not expressly granted pursuant to Section 2.1 above and the right to authorize others to do the same.

 2.4 Improvements and New Technology. Phenomix hereby specifically disclaims any obligation to grant to ActivX, and ActivX hereby
specifically disclaims any obligation to grant to Phenomix rights relating to any Improvements or New Technology made by or for them, respectively, after the Effective Date. 
  

	3.	Other Obligations of ActivX and Phenomix. 

 3.1 Patent Applications and Foreign Filing. Phenomix shall have the sole discretion and right to file, prosecute and maintain in force any and all patents and patent applications included in the Phenomix Licensed Patent Rights
including related interference and opposition proceedings. The filing, prosecution and maintenance of patents and patent applications pursuant to this Section 3.1 shall be done through patent counsel selected by Phenomix. Phenomix will instruct
patent counsel to copy ActivX on all correspondence to and from patent offices where the Phenomix Licensed Patent Rights licensed to ActivX pursuant to this Agreement are filed, and keep ActivX reasonably informed of all significant patent matters
relating to such Phenomix Licensed Patent Rights, provided that Phenomix shall be entitled to exercise its sole discretion with respect to all matters relating to patents and patent applications. Phenomix shall give ActivX such opportunity to
comment on proposed responses to office actions as is reasonably practicable. If Phenomix intends not to pursue or to abandon pursuit or maintenance of a patent or patent application included in the Phenomix Licensed Patent Rights in one or more
jurisdictions, it shall so inform ActivX. ActivX shall thereafter be entitled to have Phenomix file, pursue or maintain such patent or patent application solely at the cost of ActivX. The Parties shall reasonably cooperate in effectuating the
preceding sentence. ActivX hereby acknowledges that Phenomix shall not be responsible for the results of such activities, but shall only be required to conduct such activities in good faith. ActivX shall pay Phenomix in advance for all filing,
translation and other anticipated out-of-pocket costs associated with the exercise of such right by ActivX. ActivX shall pay Phenomix within thirty (30) days of invoice for such other costs and expenses actually incurred. ActivX shall have the
right with respect to patents and patent applications in the jurisdictions where affected to transfer such activities to counsel of its choice following notice from Phenomix that it intends not to pursue or to abandon pursuit or maintenance of a
patent or patent application included in the Phenomix Licensed Patent Rights in one or more jurisdictions. 

 ActivX (i) will instruct patent counsel to copy Phenomix on all correspondence to and from patent
offices where the Phenomix Licensed Patent Rights licensed to ActivX pursuant to this Agreement are being handled by ActivX counsel and (ii) will keep Phenomix reasonably informed of all significant patent matters relating to such Phenomix
Licensed Patent Rights. Neither ActivX nor ActivX patent counsel on behalf of ActivX shall disparage any pending or issued claims of any Phenomix patent not licensed to ActivX pursuant to this Agreement. Phenomix and ActivX shall regularly meet and
confer with regard to proposed responses to be made by ActivX to actions of the various patent offices and with regard to strategies to be employed in the pursuit of Phenomix Licensed Patent Rights being pursued or enforced by Phenomix. Due regard
shall be given to the strategies employed or to be employed by Phenomix relating to pursuit and maintenance of patent applications and patents not licensed to ActivX pursuant to this Agreement. 
 All information provided by Phenomix to ActivX pursuant to this Section 3.1, as well as pending patent applications shall be deemed to be
Confidential Information of Phenomix. Phenomix Licensed Patent Rights are pending in Australia, Canada, The People’s Republic of China, EPO, Japan, New Zealand, and South Korea, and will be filed in the United States. 
 3.2 Public Statements. The Parties agree that neither of them shall make any public statement regarding this Agreement, its terms or the other
Party hereto, without the express advance written consent of such other Party. Notwithstanding the foregoing, any public statements required by law to be made, including submissions to the Securities and Exchange Commission or stock exchange or
market system on which its securities are listed, shall be submitted to the referenced Party for review and approval, which approval shall not be unreasonably withheld or delayed. 
  

	4.	Representations and Covenants. 

 4.1
Representations and Warranties. Phenomix and ActivX each represent and warrant to the other with respect to itself that: 
 (a) Organization & Power. It is a corporation duly organized and validly existing under the laws of its state of incorporation and has all requisite corporate power and authority to enter into this Agreement; 
 (b) Authorization. It is duly authorized by all requisite action to execute, deliver and perform this Agreement and to consummate
the transactions contemplated hereby, and that the same do not conflict or cause a default with respect to its obligations under any other agreement; 
 (c) Execution & Delivery. It has duly executed and delivered this Agreement, and 
 (d) Laws, Rules & Regulations. It shall and it shall cause its Affiliates to, comply with all laws, rules and regulations applicable to the performance of its obligations hereunder, including, to the extent applicable to
such Party, the discovery, development, manufacture, distribution, import, export and sale of the Covered Product(s). 

 4.2 Disclaimer. 
 PHENOMIX HEREBY SPECIFICALLY AND EXPRESSLY DISCLAIMS THE MAKING OR APPLICABILITY OF ANY WARRANTY, WHETHER EXPRESS OR IMPLIED, REGARDING THE VALIDITY OF THE PHENOMIX LICENSED PATENT RIGHTS AND MAKES NO REPRESENTATIONS
WHATSOEVER WITH REGARD TO THE SCOPE OF THE PHENOMIX LICENSED PATENT RIGHTS OR THAT THE PHENOMIX LICENSED PATENT RIGHTS MAY BE EXPLOITED BY ACTIVX AND ITS AFFILIATES WITHOUT INFRINGING OTHER PATENTS. PHENOMIX EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED
OR EXPRESS WARRANTIES AND MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE PHENOMIX LICENSED PATENT RIGHTS. IN NO EVENT SHALL A PARTY BE LIABLE TO THE OTHER FOR INDIRECT, PUNITIVE, SPECIAL,
CONSEQUENTIAL OR EXEMPLARY DAMAGES OF ANY KIND, INCLUDING LOSS OF PROFITS AND LOSS OR INTERRUPTION OF BUSINESS, PROVIDED HOWEVER THAT THE FOREGOING PROVISION SHALL NOT BE CONSTRUED TO LIMIT A PARTY’S INDEMNIFICATION OBLIGATION UNDER THIS
LICENSE AGREEMENT FOR THIRD PARTY CLAIMS WHICH MAY INCLUDE INDIRECT, SPECIAL, CONSEQUENTIAL, PUNITIVE, EXEMPLARY AND OTHER TYPES OF DAMAGES. 
  

	5.	Infringement, Indemnity and Insurance 

 5.1
Definitions. The following definitions shall be used only for the purposes of this Article 5.0: 
 (a)
“Action” means any legal action or proceeding, or the filing of any counterclaim. 
 (b) “Infringing
Product” means a third party product that may infringe the Phenomix Licensed Patent Rights and that has regulatory approval for administration to humans. 
 5.2 Notification. With respect to any Phenomix Licensed Patent Rights, each Party shall notify the other Party in writing of any alleged or threatened infringement of which it becomes aware, and shall provide
to the other Party available evidence thereof. The Parties shall consult with respect to potential strategies for terminating such alleged or threatened infringement without litigation. 
 5.3 Defense of Declaratory Judgment Action. Phenomix shall be solely responsible for defending any assertion of invalidity or unenforceability of
Phenomix Licensed Patent Rights worldwide. 

 5.4 Enforcement of Phenomix Licensed Patent Rights. 
 (a) Non-Litigation Actions by Phenomix. Phenomix shall have the sole right, in its sole discretion, to take actions to terminate
alleged infringement identified pursuant to Section 5.2 without litigation (including the sole right to grant a license to the alleged infringer) with respect to Phenomix Licensed Patent Rights. 
 (b) Phenomix Licensed Patent Rights. Phenomix shall have the sole right, in its sole discretion, but not the obligation, to
commence and control any Action against any alleged infringement of the Phenomix Licensed Patent Rights identified pursuant to Section 5.2, at its own expense. Any damages or other recovery from an Action shall be subject to the provisions of
Section 5.5. If Phenomix, in its sole discretion, elects to not take any Action against any alleged infringement of the Phenomix Licensed Patent Rights, ActivX shall have no right to do so. 
 5.5 Recoveries. In any Action pursuant to Section 5.4, any damages or other recovery, including compensatory and other non-compensatory
damages or recovery actually received from a third party, shall be allocated first to reimburse the costs and expenses, including reasonable attorney’s fees and expert witness fees, of Phenomix commencing such Action and then to reimburse the
other Party, if any, for such costs and expenses. Such reimbursement shall be made first from any compensatory damages, including attorney’s fees and costs recovered. If any balance remains of the damages or other recovery made from the third
party after such reimbursement, any remaining compensatory damages that are attributable to lost sales of Covered Products (as defined in the Settlement Agreement) by Phenomix shall be considered Net Sales (as defined in the Settlement Agreement)
and subject to Royalties (as defined in the Settlement Agreement) pursuant to Settlement Agreement. Any remaining balance of damages or other recovery shall be apportioned as follows: 
 (a) when the Action only concerns the Phenomix Licensed Patent Rights licensed to ActivX, Phenomix and ActivX shall share equally the
remaining balance of damages or other recovery, or 
 (b) when the action concerns the Phenomix Licensed Patent Rights
licensed to ActivX and other licenses or sublicenses, the remaining balance of damages or other recovery will be apportioned by Phenomix acting reasonably, between ActivX, Phenomix and other sublicensees, with notice of such apportionment to be
given to ActivX together with the basis upon which the apportionment determination was made, subject to the right of ActivX to review the determination and submit the determination for dispute resolution pursuant to Article 7.0. 
 5.6 Indemnification. 
 (a) ActivX Indemnity. ActivX and each of its Affiliates shall indemnify and hold Phenomix, its Affiliates, and their respective current and former officers, inventors, directors, employees, students, governing board members,
trustees, faculty, medical and professional staff, consultants, contractors and agents, and their respective successors, heirs and assigns, (“Phenomix Indemnitees”) harmless from and against any and all liability, damage, loss, 

 
cost (including reasonable attorneys’ fees and expenses of litigation) and expense incurred, (a “Loss”) resulting from or imposed upon the
Phenomix Indemnitees or any of them by any third party in connection with any claims, suits, actions, demands or judgments, including claims for bodily injury or property damage (but excluding any and all such matters pertaining to patent
infringement), (i) relating to the use of the Phenomix Licensed Patent Rights and/or the development, manufacture, use, distribution or sale of any Covered Product by ActivX or its Affiliates, or their respective employees, consultants,
contractors and agents or (ii) due to the negligence or willful misconduct of ActivX, its Affiliates or their respective employees, consultants, contractors and agents; provided, however, that the foregoing indemnity shall not apply to any Loss
to the extent that such Loss was caused by the negligent or willful misconduct of Phenomix or its Affiliates. 
 (b)
Phenomix Indemnity. Phenomix shall indemnify and hold ActivX and its Affiliates, and their respective officers, directors, employees, consultants, contractors and agents, and their respective successors, heirs and assigns, (“ActivX
Indemnitees”) harmless from and against any and all liability, damage, loss, cost (including reasonable attorneys’ fees and expenses of litigation) and expense incurred (a “Loss”), resulting from or imposed upon the ActivX
Indemnitees or any of them by any third party in connection with any claims, suits, actions, demands or judgments, including any claim of bodily injury or property damage (but excluding any and all such matters pertaining to patent infringement),
(i) relating to the development, manufacture, use, distribution or sale of any product by Phenomix or its licensees or sublicensees (other than ActivX and its Affiliates) or (ii) due to the negligence or willful misconduct of Phenomix, its
Affiliates or their respective employees, consultants, contractors and agents; provided, however, that the foregoing indemnity shall not apply to any Loss to the extent that such Loss was caused by the negligent or willful misconduct of ActivX or
its Affiliates. 
 (c) Claims Procedures. A Party entitled to be indemnified by the other Party (an “Indemnified
Party”) pursuant to Section 5.6(a) or (b) hereof shall give written notice to the other Party (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any threatened or asserted claim as to
which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting there from, provided: 
 (i) that counsel for the Indemnifying Party, who shall conduct the defense of such claim or any litigation resulting there from, shall be
approved by the Indemnified Party (which approval shall not be unreasonably withheld), and the Indemnified Party may participate in such defense at such Indemnified Party’s expense (unless (i) the employment of counsel by such Indemnified
Party has been authorized by the Indemnifying Party; or (ii) the Indemnified Party shall have reasonably concluded that there may be a conflict of interest between the Indemnifying Party and the Indemnified Party in the defense of such action,
in each of which cases the Indemnifying Party shall pay the reasonable fees and expenses of one law firm serving as counsel for the Indemnified Party, which law firm shall be subject to approval, not to be unreasonably withheld, by the Indemnifying
Party); 

 (ii) the failure of any Indemnified Party to give notice as provided herein shall not
relieve the Indemnifying Party of its obligations under this Agreement to the extent that such failure to give notice did not result in prejudice to the Indemnifying Party or the Indemnifying Party’s insurer; 
 (iii) the Indemnifying Party, in the defense of any such claim or litigation, shall not, except with the approval of the Indemnified Party
(which approval shall not be unreasonably withheld), consent to entry of any judgment or enter into any settlement which, (i) would result in injunctive or other relief being imposed against the Indemnified Party; or (ii) does not include
as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation; and 
 (iv) the Indemnified Party shall furnish such information regarding itself or the claim in question as the Indemnifying Party may
reasonably request in writing, and shall be reasonably required in connection with the defense of such claim or litigation resulting there from. 
 5.7 Compliance. The Parties shall comply fully with all applicable laws and regulations in connection with their respective activities under this Agreement. 
 5.8 Insurance. 
 (a)
Coverage. ActivX shall, at all times during the term of this Agreement and until five (5) years after expiration of the last batch of Covered Products sold or manufactured hereunder by ActivX or its Affiliates, obtain and maintain at its
own cost and expense, comprehensive commercial liability insurance, including, but not limited to, product liability and contractual liability insurance, and errors and omissions coverage, with respect to its activities hereunder. Such insurance
shall be in such amounts subject to such deductibles as the Parties may agree based upon standards prevailing in the industry at the time, but under no circumstances shall be less than: (i) * * * dollars ($* * *) per occurrence for damage,
injury and/or death to persons prior to regulatory authority approval of an Covered Product; (ii) * * * dollars ($* * *) per occurrence damage, injury and/or death to persons after regulatory authority approval of an Covered Product; and * * *
dollars ($* * *) per occurrence for damage/or injury to property. Such insurance shall be written to cover, among other things, claims incurred, discovered, manifested, or made in connection with clinical development and commercial sale of Covered
Products in the Territory. Upon the written request of Phenomix, ActivX shall provide to Phenomix copies of its Certificates of Insurance. 
 (b) Additional Requirements. All of the liability policies set out in (a) shall be primary and non-contributory, shall include as additional named insured Phenomix and such other persons as the Phenomix
may determine in its discretion (subject to wording in such policies restricting coverage to those claims for which the ActivX may be responsible hereunder and contain a waiver of subrogation in favor of Phenomix or Phenomix’s designee. Each
policy will be endorsed to provide that the insurers will give Phenomix, or its designee, not less than 
  

	* * *	Confidential Information, indicated by ***, has been omitted from this filing and filed separately with the Securities and Exchange Commission. 

 thirty (30) days prior written notice of any cancellation or material change in coverage. If ActivX
fails to place or maintain insurance as required under this Agreement, Phenomix or its designee may place and maintain such policy and all premium and other costs incurred by Phenomix or its designee will be paid by the ActivX to the other Phenomix
or its designee on demand or failing payment may be deducted by Phenomix or its designee from any amount then or thereafter due to the ActivX under this Agreement. 
  

	6.	Termination. 

 6.1 Early Termination of
Licenses. Notwithstanding the foregoing, and subject to the limitations set forth below, Phenomix shall be entitled in the following circumstances to terminate this Agreement: 
 (a) Material Breach. If ActivX materially breaches this Agreement, Phenomix shall have the right, at its sole election, to
terminate this Agreement upon thirty (30) days prior written notice to ActivX; provided, however, that if ActivX shall cure the breach or default within the thirty (30) day period, all such licenses and agreements shall continue in full
force and effect. 
 (b) Insolvency, Bankruptcy. If ActivX shall file a petition in bankruptcy or if an involuntary
petition shall be filed against it and such petition shall not be dismissed within sixty (60) days, or if it shall become insolvent or admit its inability to pay its debts when due, or if a receiver or guardian shall be appointed for it, then
all licenses granted to such party under this Agreement shall immediately terminate. 
 (c) Challenge of Phenomix Licensed
Patent Rights. During the Term, should ActivX or any of its Affiliates challenge the validity of any Phenomix Licensed Patent Rights, or support, directly or indirectly, any such challenge to any Phenomix Licensed Patent Rights, Phenomix shall
be entitled to terminate this Agreement upon thirty (30) days prior written notice to ActivX. 
 (d) Breach of
Settlement Agreement. If ActivX materially breaches that certain Settlement Agreement of even date herewith entered into by and among Phenomix, ActivX, David Campbell, David Winn, and Juan Betancort, Phenomix shall have the right, at its sole
election, to terminate this Agreement upon thirty (30) days prior written notice to ActivX; provided, however, that if ActivX shall cure such breach or default within the thirty (30) day period, this Agreement shall continue in full force
and effect. 
 6.2 Accrued Obligations. Upon termination of the ActivX license granted under this Agreement for any reason, each of
Phenomix and ActivX shall remain liable for those obligations that accrued with respect to such license prior to the effective date of the termination. ActivX may, for a period of no longer than six (6) months after the effective date of the
termination of the ActivX License, complete and sell any or all Covered Products that it can demonstrate were in the process of manufacture or in inventory on the effective date of the termination. 

	7.	Dispute Resolution 

 7.1 Negotiation of
Parties. In the event of any dispute with respect to the interpretation of any provision of this Agreement or with respect to the performance of either party under this Agreement, either party may at any time provide the other party written
notice specifying the terms of such disagreement in reasonable detail. As soon as practicable after receipt of such notice, the Chief Executive Officers of both Phenomix and ActivX shall meet at a mutually agreed upon time and location for the
purpose of resolving such disagreement. They shall engage in good faith discussions and/or negotiations for a period of up to thirty (30) days to resolve the disagreement or negotiate an interpretation or revision of the applicable portion of
this Agreement which is mutually agreeable to both parties, without the necessity of formal procedures relating thereto. During the course of such discussion and/or negotiation, the parties shall reasonably cooperate and provide information that is
not materially confidential in order so that each of the parties may be fully informed with respect to the issues in dispute. 
 7.2
Further Procedures. If implementation of the procedures set forth in Section 7.1 do not result in resolution of a dispute, each party shall have the right to refer the dispute first to mediation before a retired judge at JAMS or the
Honorable Gerald J. Lewis. If such mediation is unsuccessful, such dispute shall be submitted to arbitration before JAMS using the AAA Commercial Arbitration Rules. Each party shall submit a list of three (3) potential arbitrators and shall
meet and confer in good faith to select such arbitrator. If the parties are unable to agree upon an arbitrator, JAMS shall select the arbitrator from the lists provided by the respective parties. The arbitrator shall have the power to grant
injunctive and other provisional or equitable relief, including preliminary orders and reasonable discovery orders. The parties hereby knowingly waive their respective rights to file an action in any court and knowingly waive their rights to a jury
trial. For the avoidance of doubt, the Parties specifically agree that this provision does not apply to any allegations of patent infringement or to the breach or threatened breach of the confidentiality provisions of this Agreement. 
  

	8.	General Provisions 

 8.1 Remedies. The
parties acknowledge and agree that, in the event of a breach or a threatened breach by either Party of the confidentiality provisions of this Agreement or other provisions for which it will have no adequate remedy at law, the other party may suffer
irreparable damage and, accordingly, shall be entitled to injunctive and other equitable remedies to prevent or restrain such breach or threatened breach, without the necessity of posting any bond or surety, in addition to any other remedy they
might have at law or at equity. 
 8.2 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of
California in force therein without regard to its conflict of law rules. Subject to Sections 7.1 and 7.2, all parties agree that by executing this Agreement they consent to the exclusive jurisdiction of the courts of California. 
 8.3 Confidentiality. It is contemplated that in the course of the performance of this Agreement each Party may, from time to time, disclose
Confidential Information to the other. Each Party agrees that for the Term and for a period of five (5) years thereafter, the receiving 

 
Party shall keep confidential and shall not publish or otherwise disclose, and will take all reasonable steps to prevent disclosure of, such Confidential
Information and will not use any Confidential Information except for the limited purposes set forth in this Agreement; provided, however, that no provision of this Agreement shall be construed to preclude such disclosure of
Confidential Information as may be necessary or appropriate (i) to obtain from any governmental agency any necessary approval or (ii) to obtain patents that are selection inventions that are based on the Phenomix Licensed Patent Rights
provided, further, however, that the Party whose information is to be disclosed shall be notified as soon as possible and the Party that is being required to disclose such information shall, if requested by the Party whose information is to be
disclosed, use reasonable good faith efforts, at the expense of the requesting Party, to assist in seeking a protective order (or equivalent) with respect to such disclosure or otherwise avoid making such disclosure. 
 8.4 Amendment and Waiver No provision of or right under this Agreement shall be deemed to have been waived by any act or acquiescence on the part
of any party, its agents or employees, but only by an instrument in writing signed by an authorized officer of such party. No waiver by either party of any breach of this Agreement by any other party shall be effective as to any other breach,
whether of the same or any other term or condition and whether occurring before or after the date of such waiver. 
 8.5 Intellectual
Property 
 (a) Trademarks. All respective names, trademarks, trade names, labels, or other designations used shall
are, and the same shall remain, the property of their respective owners. 
 (b) Patents. ActivX agrees to mark the
Covered Products or their packaging sold in the United States with all applicable U.S. patent numbers and similarly to indicate “Patent Pending” status. All Covered Products manufactured in, shipped to, or sold in other countries shall be
marked in such a manner as to protect and preserve the Patent Rights in such countries. 
 8.6 Independent Contractors. Each party
represents that it is acting on its own behalf as an independent contractor and is not acting as an agent for or on behalf of any third party. This Agreement and the relations hereby established by and among Phenomix, ActivX do not constitute a
partnership, joint venture, agency or contract of employment between them. 
 8.7 Assignment. Without limitation to the rights set
forth in Section 2.2, this Agreement and ActivX’s rights and obligations hereunder may not be sold, assigned or transferred to any third party without the consent of Phenomix. This requirement also applies to any change of control of
ActivX, it being acknowledged that unless the consent of Phenomix is received prior to the change of control, this Agreement may be terminated by Phenomix. 
 8.8 Successors and Assigns. This Agreement shall bind and inure to the benefit of the parties hereto and their respective successors and permitted assigns. 

 8.9 Notices All communications hereunder shall be in writing and shall be deemed to have been duly
given upon receipt by the addressee at the addresses set forth below, or such other address as either party may specify by notice sent in accordance with this section: 
  

	 	If to ActivX:	ActivX Biosciences, Inc. 

	 	    	11025 North Torrey Pines Road 

	 	    	Suite 120 

	 	    	La Jolla, California 92037 

	 	    	Attention: John W. Kozarich, Ph.D. 

  

	 	With a copy to:	Pillsbury Winthrop Shaw Pittman LLP 

	 	    	101 West Broadway, Suite 1800 

	 	    	San Diego, California 92101 

	 	    	Attention: George S. Howard, Esq. 

  

	 	If to Phenomix:	Phenomix Corporation 

	 	    	5871 Oberlin Drive 

	 	    	Suite 200 

	 	    	San Diego, California 92121 

	 	    	Attention: Laura K. Shawver, Ph.D. 

  

	 	With a copy to:	Heller Ehrman LLP 

	 	    	4350 La Jolla Village Drive 

	 	     
	 7th Floor

	 	    	San Diego, California 92122 

	 	    	Attention: Richard A. Kaufman, Esq. 

 8.10
Severability. In the event any provision of this Agreement shall for any reason be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other term or provision
hereof. The parties agree that they will negotiate in good faith or will permit a court or arbitrator to replace any provision hereof so held invalid, illegal or unenforceable with a valid provision which is as similar as possible in substance to
the invalid, illegal or unenforceable provision. 
 8.11 Conflict or Inconsistency In the event of any conflict or inconsistency
between the terms and conditions hereof and any terms or conditions set forth in any document relating to the transactions contemplated by this Agreement, the terms and conditions set forth in this Agreement shall prevail. 
 8.12 Captions. Captions of the Sections and subsections of this Agreement are for reference purposes only and do not constitute terms or
conditions of this Agreement and shall not limit or affect the terms and conditions hereof, 
 8.13 Word Meanings. Words such as
herein, hereinafter, hereof and hereunder refer to this Agreement as a whole and not merely to a Section or paragraph in which such words appear, unless the context otherwise requires. The singular shall include the plural, and
each masculine, feminine and neuter reference shall include and refer also to the others, unless the context otherwise requires. 

 8.14 Entire Agreement This Agreement and the Settlement Agreement contain the entire understanding
of each of the parties hereto with respect to the transactions and matters contemplated hereby, including without limitation any licensing of the Phenomix Licensed Patent Rights, supersedes all prior agreements and understandings relating to the
subject matter hereof, and no representations, inducements, promises or agreements, whether oral or otherwise, between such parties not contained herein or incorporated herein by reference shall be of any force or affect. 
 8.15 Cooperation. The Parties hereby agree to cooperate reasonably in all regards to effectuate the provisions of this Agreement. 
 8.16 Rules of Construction. The parties agree that they have participated equally in the formation of this Agreement and that the language and
terms of this Agreement shall not be presumptively construed against any of them. 
 8.17 Counterparts. This Agreement may be executed
in multiple counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. In making proof of this Agreement, it shall not be necessary to produce or account for more than one such
counterpart. 
 8.18 Survival. Sections 4.2, 5.6, and 5.8 and Articles 7 and 8 shall survive the expiration or early termination of
this Agreement. 
 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed and delivered by their respective duly
authorized officers. 
  

			
	PHENOMIX CORPORATION
		
	By:	 	/s/ Laura Shawver
	Name:	 	Laura Shawver
	Title:	 	President and CEO

  

			
	ACTIVX BIOSCIENCES, INC.
		
	By:	 	/s/ John W. Kozarich
	Name:	 	John W. Kozarich
	Title:	 	Chairman and President

 EXHIBIT A 
 Licensed Patent Rights 
 * * * 

	* * *	Confidential Information, indicated by ***, has been omitted from this filing and filed separately with the Securities and Exchange Commission. 

 EXHIBIT B 
 * * * 

	* * *	Confidential Information, indicated by ***, has been omitted from this filing and filed separately with the Securities and Exchange Commission.Agreement dated January, 24, 2008 between the Company and Andrew J. Filipowski

 Exhibit 10.1 
 AGREEMENT 
 This Agreement, dated as of January 24, 2008 (“Agreement”), is by and
among CRYO-CELL International, Inc., a Delaware corporation (the “Company”), and the other persons and entities that are signatories hereto (collectively, the “Holders,” and each, individually, a “Holder”), each of whom
is a holder of common shares, par value $.01, of the Company (the “Shares”). 
 WHEREAS, pursuant to an agreement with the Company,
upon recommendation of the Governance Committee of the Board of Directors of the Company (the “Board”), the Board nominated Andrew J. Filipowski for election as a director of the Company at the Company’s annual meeting of stockholders
held on July 16, 2007 (the “2007 Annual Meeting”); 
 WHEREAS, the Delaware Court of Chancery has invalidated the results of
the election of directors at the 2007 Annual Meeting, reinstated the members of the Board that were in office prior to the 2007 Annual Meeting, and ordered the Company to hold a new election of directors to the Board at a special meeting of
shareholders to be held on March 4, 2008 (the “Special Meeting”); 
 WHEREAS, the Board has determined that it is in the best
interests of the Company and its shareholders to nominate Mr. Filipowski for election as a director of the Company to serve at least until the Company’s 2009 annual meeting of shareholders (the “2009 Annual Meeting”), provided
that the Holders agree to certain limitations on their activities as described herein, and the Holders are willing to agree to such limitations. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties
hereto, intending to be legally bound hereby, agree as follows: 
 1. Representations and Warranties of the Company. The Company
hereby represents and warrants to the Holders that (i) this Agreement has been duly authorized, executed and delivered by the Company, and is a valid and binding obligation of the Company, enforceable against the Company in accordance with its
terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles; and
(ii) neither the execution of this Agreement nor the consummation of any of the transactions contemplated hereby nor the fulfillment of the terms hereof, in each case in accordance with the terms hereof, will conflict with, result in a breach
or violation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to the terms of any indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement or
other agreement, obligation, condition, covenant or instrument to which the Company or any of its subsidiaries is a party or bound or to which its or their property is subject. 
 2. Representations and Warranties of the Holders. Each of the Holders represents and warrants to the Company that this Agreement has been duly
authorized, executed and delivered by such Holder, and is a valid and binding obligation of such Holder, enforceable against such Holder in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, 

 
insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity
principles. 
 3. Board of Directors Matters. 
 (a) The Board agrees to nominate Andrew J. Filipowski as part of the management’s slate of nominees for election to the Board at the Special Meeting and at any subsequent meeting of stockholders at which
directors are to be elected prior to the 2009 Annual Meeting (each such meeting, a “Subsequent Meeting”). 
 (b) Each of the
Holders agrees to vote all of the Shares for which he or it has voting power, in favor of each person nominated by the Board or any committee thereof, and not to subsequently change or revoke such vote or vote for any other nominees besides each
person nominated by the Board or any committee thereof at the Special Meeting or any Subsequent Meeting. 
 4. Standstill. 

(a) Except for actions expressly permitted by this Agreement, each of the Holders agrees that (i) from the date of this Agreement until the
Special Meeting is permanently adjourned and (ii) if Mr. Filipowski is elected as a director at the Special Meeting, until the earlier of (x) the 2009 Annual Meeting or (y) such earlier time as Andrew J. Filipowski is no longer a
director of the Company for a reason other than his voluntary resignation from the Board, without the prior written consent of the Board specifically expressed in a written resolution adopted by a majority vote of the entire Board, neither such
Holder nor any of its Affiliates or Associates under its control or direction will, and it will cause each of its Affiliates and Associates under its control not to, directly or indirectly, in any manner: (A) engage in any solicitation of
proxies or consents to vote any voting securities of the Company in opposition to the recommendations of the Board or become a participant in any election contest with respect to the Company; (B) otherwise take any action to obtain
representation on the Board; (C) take any action that is designed to require the Company to make a public announcement regarding its strategic alternatives; (D) enter into any agreements with any third party with respect to any of the
foregoing; or (E) make any public announcement with respect to any of the foregoing, except as advised by counsel to comply with applicable law and regulations. 
 (b) As used in this Agreement, the terms “Affiliate” and “Associate” shall have the respective meanings set forth in Rule 12b-2 promulgated by the Securities and Exchange Commission (the
“SEC”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”); the terms “beneficial owner” and “beneficial ownership” shall have the same meanings as set forth in Rule 13d-3 promulgated by
the SEC under the Exchange Act; and the terms “person” or “persons” shall mean any individual, corporation (including not-for-profit), general or limited partnership, limited liability company, joint venture, estate, trust,
association, organization or other entity of any kind or nature; and “group” shall have the meaning as set forth in Rule 13d-5 promulgated by the SEC under the Exchange Act. 
  

 2 

 5. Confidentiality. The Holders (each, a “Recipient”) each acknowledge the confidential
and proprietary nature of the Confidential Information (as defined below) and agree that the Confidential Information (a) will be kept confidential by Recipient and Recipient’s Representatives and (b) will not be disclosed by
Recipient (except to other Recipients and their Affiliates and Associates and such person’s Representatives to the extent contemplated by this Agreement) or by Recipient’s Representatives (as defined below) to any person except with the
specific prior written consent of the Company or except as expressly otherwise permitted by this Agreement. It is understood that (x) Recipient may disclose Confidential Information only to those of Recipient’s Representatives who are
informed by Recipient of the confidential nature of the Confidential Information and the obligations of this Agreement and (y) Recipient shall be responsible for the breach of the provisions of this Section 5 by Recipient’s
Representatives. As used in this Agreement, the term “Confidential Information” means and includes any and all of the information concerning the business and affairs of the Company that may hereafter be disclosed to Recipient by the
Company or by the directors, officers, employees, agents, consultants, advisors or other representatives, including legal counsel, accountants and financial advisors (“Representatives”) of the Company; provided that “Confidential
Information” shall not include information that (a) was in or enters the public domain or was or becomes generally available to the public other than as a result of disclosure by Recipient or any Representative thereof, (b) was
independently acquired by Recipient without violating any of the obligations of Recipient or its Representatives under this Agreement, or under any other contractual, legal, fiduciary or binding obligation of Recipient or its Representatives with or
to the Company, (c) was available, or becomes available, to Recipient on a nonconfidential basis other than as a result of its disclosure to Recipient by the Company or any Representative of the Company, but only if to the knowledge of
Recipient the source of such information is not bound by a confidentiality agreement with the Company or is not otherwise prohibited from transmitting the information to Recipient or Recipient’s Representatives by a contractual, legal,
fiduciary or other binding obligation with or to the Company, or (d) was independently developed by Recipient or its Representatives without reference to any other Confidential Information. 
 6. Specific Performance. Each of the Holders, on the one hand, and the Company, on the other hand, acknowledges and agrees that irreparable injury
to the other party hereto would occur in the event any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached and that such injury would not be adequately compensable in damages. It
is accordingly agreed that the Holders or any of them, on the one hand, and the Company, on the other hand (the “Moving Party”), shall each be entitled to specific enforcement of, and injunctive relief to prevent any violation of, the
terms hereof, and the other party hereto will not take action, directly or indirectly, in opposition to the Moving Party seeking such relief on the grounds that any other remedy or relief is available at law or in equity. 
  

 3 

 7. Jurisdiction; Applicable Law. Each of the parties hereto (a) consents to submit itself to
the personal jurisdiction of the federal or state courts of the State of Delaware in the event any dispute arises out of this Agreement or the transactions contemplated by this Agreement, (b) agrees that it shall not attempt to deny or defeat
such personal jurisdiction by motion or other request for leave from any such court, (c) agrees that it shall not bring any action relating to this Agreement or the transactions contemplated by this Agreement in any court other than the federal
or state courts of the State of Delaware, and each of the parties irrevocably waives the right to trial by jury and (d) each of the parties irrevocably consents to service of process by first class certified mail, return receipt requested,
postage prepaid, to the address of such parties’ principal place of business or as otherwise provided by applicable law. THIS AGREEMENT SHALL BE GOVERNED IN ALL RESPECTS, INCLUDING VALIDITY, INTERPRETATION AND EFFECT, BY THE LAWS OF THE STATE
OF DELAWARE APPLICABLE TO CONTRACTS EXECUTED AND TO BE PERFORMED WHOLLY WITHIN SUCH STATE WITHOUT GIVING EFFECT TO THE CHOICE OF LAW PRINCIPLES OF SUCH STATE. 
 8. Stockholder Representative. Each of the Holders hereby irrevocably appoints Andrew J. Filipowski as such member’s attorney-in-fact and representative (the “Stockholder Representative”), in
such member’s place and stead, to do any and all things and to execute any and all documents and give and receive any and all notices or instructions in connection with this Agreement and the transactions contemplated hereby. The Company shall
be entitled to rely, as being binding on each of the Holders, upon any action taken by the Stockholder Representative or upon any document, notice, instruction or other writing given or executed by the Stockholder Representative. 
 9. Severability. If at any time subsequent to the date hereof, any provision of this Agreement shall be held by any court of competent
jurisdiction to be illegal, void or unenforceable, such provision shall be of no force and effect, but the illegality or unenforceability of such provision shall have no effect upon the legality or enforceability of any other provision of this
Agreement. 
 10. Counterparts. This Agreement may be executed in two or more counterparts which together shall constitute a single
agreement. 
 11. Entire Agreement; Amendment. This Agreement contains the entire understanding of the parties hereto with respect to
its subject matter. There are no restrictions, agreements, promises, representations, warranties, covenants or undertakings other than those expressly set forth herein. This Agreement may be amended only by a written instrument duly executed by the
parties hereto, or in the case of the Holders, the Stockholder Representative, or their respective successors or assigns. 
 [Signature
Page Follows] 
  

 4 

 [Signature Page to Agreement] 
 IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by the duly authorized signatories of the parties as of the date hereof.

  

			
	CRYO-CELL INTERNATIONAL, INC.
		
	By:	 	 /s/ Mercedes Walton

	Name:	 	Mercedes Walton
	Title:	 	Chairman and Chief Executive Officer
	
	 /s/ Andrew J. Filipowski

	Andrew J. Filipowski
	
	 /s/ Matthew G. Roszak

	Matthew G. Roszak
	
	SILKROAD EQUITY LLC
		
	By:	 	 /s/ Matthew G. Roszak

		 	Matthew G. Roszak, individually and as a Managing Member of SilkRoad Equity LLC

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}]]